Opinion|Videos|February 27, 2026
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management
Author(s)Joel Neal, MD, PhD, Sarah B. Goldberg, MD, MPH
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss the clinical role of amivantamab plus lazertinib in EGFR-mutated NSCLC.
Advertisement
Episodes in this series
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, evaluate the clinical data supporting amivantamab plus lazertinib in EGFR-mutated NSCLC. Neal outlines the mechanistic rationale for dual EGFR and MET targeting and reviews efficacy outcomes from pivotal studies. Goldberg contextualizes this combination within current sequencing strategies and frontline decision-making.
Advertisement
Related to this article
Bringing some or all clinical trial-related activities directly to patients can help overcome barriers that prevent many people from participating.
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.
High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL
5